Frequent inactivation of hSRBC in ovarian cancers by promoter CpG island hypermethylation

References

• Annual report of gynecologic cancer registry program in Korea for 2004 (Jan. 1st, 2004-Dec. 31st, 2004). Korean J Obstet Gynecol. 2004;50:28–78.
   Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Human epithelial ovarian cancer allelotype. Cancer Res. 1993; 53(10 Suppl):2393–8.
   Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28.
   Google Scholar
• Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res. 1997;57:387–90.
   Google Scholar
• Gabra H, Taylor L, Cohen BB, Lessels A, Eccles DM, Leonard RC, Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer. 1995;72:367–75.
   Google Scholar
• Davis M, Hitchcock A, Foulkes WD, Campbell IG. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res. 1996;56:741–4.
   PubMed Web of Science ®Google Scholar
• Launonen V, Stenback F, Puistola U, Bloigu R, Huusko P, Kytola S, Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol Oncol. 1998;71:299–304.
   Google Scholar
• Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet. 2000;122:49–54.
   Google Scholar
• Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L, Pfleiderer A. Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation. Cancer. 1993;72:2423–32.
   Google Scholar
• Roy D, Calaf G, Hei TK. Allelic imbalance at 11p15.5-15.4 correlated with c-Ha-ras mutation during radiation-induced neoplastic transformation of human breast epithelial cells. Int J Cancer. 2003;103:730–7.
   PubMed Web of Science ®Google Scholar
• Zhao B, Bepler G. Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer. Oncogene. 2001;20:8154–64.
   PubMed Web of Science ®Google Scholar
• Tran YK, Newsham IF. High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res. 1996;56:2916–21.
   Google Scholar
• Panani AD, Ferti AD, Raptis SA, Roussos C. Novel recurrent structural chromosomal aberrations in primary bladder cancer. Anticancer Res. 2004;24:2967–74.
   PubMed Web of Science ®Google Scholar
• Kozlowski L, Filipowski T, Rucinska M, Pepinski W, Janica J, Skawronska M, Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy. Neoplasma. 2006;53:440–3.
   PubMed Web of Science ®Google Scholar
• Moskaluk CA, Rumpel CA. Allelic deletion in 11p15 is a common occurrence in esophageal and gastric adenocarcinoma. Cancer. 1998;83:232–9.
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Rao PH, Ladanyi M, Altorki N, Albino AP, Kelsen DP, 11p13-15 is a specific region of chromosomal rearrangement in gastric and esophageal adenocarcinomas. Cancer Res. 1990;50:6410–6.
   Google Scholar
• Vandamme B, Lissens W, Amfo K, De Sutter P, Bourgain C, Vamos E, Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res. 1992;52:6646–52.
   Google Scholar
• Weitzel JN, Patel J, Smith DM, Goodman A, Safaii H, Ball HG. Molecular genetic changes associated with ovarian cancer. Gynecol Oncol. 1994;55:245–52.
   Google Scholar
• Xu XL, Wu LC, Du F, Davis A, Peyton M, Tomizawa Y, Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res. 2001;61:7943–9.
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Fong KM, Geradts J, Xu X, Seidl S, End-Pfutzenreuter A, Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene. 2005;24:6249–55.
   PubMed Web of Science ®Google Scholar
• Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer. 2008;122:1573–84.
   PubMed Web of Science ®Google Scholar
• Chi SG, Kim HJ, Park BJ, Min HJ, Park JH, Kim YW, Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in patients with Cowden disease. Gastroenterology. 1998;115:1084–9.
   Google Scholar
• Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst. 1997;89:66–71.
   PubMed Web of Science ®Google Scholar
• Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.
   PubMed Web of Science ®Google Scholar